CTX130 for T-Cell Lymphoma

Phase-Based Progress Estimates
Research Site 1, Houston, TXT-Cell LymphomaCTX130 - Biological
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective in people with relapsed or refractory T or B cell malignancies.

Eligible Conditions
  • T-Cell Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: From CTX130 infusion up to 60 months post-infusion]

Day 28
Part A (dose escalation)
Month 60
Part B (cohort expansion)
Month 60
Progression Free Survival
Month 60
Overall Survival

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

45 Total Participants · 1 Treatment Group

Primary Treatment: CTX130 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: CTX130 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from ctx130 infusion up to 60 months post-infusion]

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor
6 Previous Clinical Trials
446 Total Patients Enrolled
Matthias Will, MDStudy DirectorCRISPR Therapeutics
2 Previous Clinical Trials
176 Total Patients Enrolled
Anjali Sharma, MDStudy DirectorCRISPR Therapeutics
1 Previous Clinical Trials
107 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your kidneys, liver, heart, and lungs are working properly.

Frequently Asked Questions

How many participants are currently partaking in this clinical experiment?

"This trial necessitates the recruitment of 45 volunteers who adhere to its inclusion criteria. Potential participants can join at any one of two primary research sites - Duarte, California and Houston, Texas." - Anonymous Online Contributor

Unverified Answer

Are there any clinical research centers in North America conducting this trial?

"Presently, this trial is operating from 9 distinct sites. These locations include Duarte, Houston and Salt Lake City as well as 6 other places of residence. It would be most beneficial to select the closest location in order to limit any possible travelling inconveniences should you choose to take part." - Anonymous Online Contributor

Unverified Answer

Is there still capacity to enroll individuals in this experiment?

"Affirmative. Clinicaltrials.gov provides evidence that this experiment is presently recruiting participants, which it has been doing since July 31st 2020. 45 applicants are desired from 9 separate locations for the trial's duration." - Anonymous Online Contributor

Unverified Answer

Has the FDA given its stamp of approval for CTX130?

"As this is an early-stage trial, the safety of CTX130 has been evaluated as a 1 on Power's scale. This rating indicates that there is limited data available to assess its efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.